• 1 January 1976
    • journal article
    • research article
    • Vol. 37 (5), 357-366
Abstract
The effectiveness and clinical indications of terbutaline as a bronchodilator were analyzed by the s.c., oral and aerosol route in 56 patients. A significant improvement in air flow rates both in major and smaller airways was achieved by all routes of administration. The inhalation route offered the fastest onset of action, maximal response and longest duration. Similar trends, but of decreased magnitude, were seen following the s.c. and oral routes, Overall analysis of results did not indicate a definite dose-response dependency within the aerosol and oral routes at the tested dosages, whereas the incidence of side effects was clearly dose-dependent. For maintenance therapy treatment should begin with oral terbutaline 2.5 mg every 6-8 h and this dose should be adjusted according to the clinical response. For the treatment of acute bronchospasm 0.50 mg or 0.25 mg s.c., or a dose as low as 0.375 mg by aerosol, would be highly effective within 5 min. A combination of oral and aerosol administration represents a highly effective synergistic combination for most clinical situations requiring maintenance therapy.

This publication has 1 reference indexed in Scilit: